Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:50 PM
Ignite Modification Date:
2025-12-24 @ 10:50 PM
NCT ID:
NCT06926569
Eligibility Criteria:
Inclusion Criteria:
1. Aged 18 and above
2. ART naive
3. HIV positive individuals
4. Confirmed Talaromycosis diagnosed by culture/microscopy
Exclusion Criteria:
1. Pregnancy or lactating women;
2. Central nervous system involvement (assessed either through clinical manifestations or cerebrospinal fluid analysis);
3. Known allergy to AMB d/L-AMB, or the concomitant use of medications known to interact with AMB d/L-AMB;
4. Alanine aminotransferase or aspartate aminotransferase levels exceeding 400 U/L;
5. Absolute neutrophil count below 500/mm3;
6. Creatinine clearance below 30 mL/min (calculated using the Cockcroft and Gault equation);
7. Concurrent diagnosis of cryptococcal meningitis;
8. Concurrent treatment with rifampicin;
9. Previous treatment for talaromycosis lasting more than 48 hours.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06926569
Study Brief:
Protocol Section:
NCT06926569